Cancer-Fighting CAR-T therapy tested against arthritis
NCT ID NCT06475495
Summary
This early-stage study is testing whether a personalized cell therapy called CAR-T (KYV-101) can work better than the standard drug rituximab for people with severe, treatment-resistant rheumatoid arthritis. It will enroll 13 patients to compare the safety of both treatments and see if they can eliminate a key disease marker (ACPA) and lead to long-term, drug-free remission. Participants will be followed for one year to monitor their health and disease activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.